3 completed, 1 not yet recruiting, 1 recruiting, 1 unknown. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 3, Not yet recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
Follow Myocardial Fibrosis: new trials by email Literature Review of Myocardial Fibrosis trials Research Report on Myocardial Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hormone thERapy Effects on BRAin-HEART Health During the Menopausal Transition Transdermal estradiol, Standard of care - non hormonal - Menopause, Perimenopause | Phase 4 | Not yet recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 100 | 2026-11-01 | 2026-07-29 |
| Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction Sacubitril-valsartan, Valsartan - Heart Failure With Preserved Ejection Fraction, Myocardial Fibrosis | Phase 4 | Withdrawn | Brigham and Women's Hospital | 2026-08-27 | 2026-08-31 | |
| High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment Elucirem (Gadopiclenol) - Myocardial Fibrosis | Phase 4 | Recruiting | Johns Hopkins University | 25 | 2025-08-01 | 2026-04-13 |
| Ventricular Tachycardia Ablation and Myocardial Scar Characterization With Magnetic Resonance Group 1, CMR-guided/aided VT ablation, Group 2, CMR-aided VT ablation, Group 3, Electroanatomical guided ablation - Ventricular Tachycardia, Myocardial Fibrosis | Phase 4 | Completed | Azienda Ospedaliero, Universitaria Pisana | 104 | 2020-08-03 | 2025-12-15 |
| Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2 dapagliflozin, Placebo - Type 2 Diabetes Mellitus, Myocardial Fibrosis | Phase 4 | Completed | University of Washington | 62 | 2019-02-26 | 2023-12-29 |
| Role of Immune Responses After Acute Myocardial Infarction Rosuvastatin plus clopidogrel, Rosuvastatin plus ticagrelor, Simvastatin plus clopidogrel - Myocardial Fibrosis | Phase 4 | Unknown | Federal University of São Paulo | 300 | 2015-05-01 | 2015-06-11 |
| Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy Spironolactone, Placebo - Myocardial Fibrosis, Hypertrophic Cardiomyopathy | Phase 4 | Completed | Tufts Medical Center | 53 | 2007-11-01 | 2021-04-27 |
Cardiomyopathy, Hypertrophic (1) · Diabetes Mellitus, Type 2 (1) · Fibrosis (1) · Myocarditis (1) · Tachycardia, Ventricular (1)
Cardiovascular Diseases (3) · Heart Diseases (3) · Cardiomyopathies (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Aortic Stenosis, Subvalvular (1) · Aortic Valve Disease (1) · Aortic Valve Stenosis (1) · Arrhythmias, Cardiac (1) · Cardiac Conduction System Disease (1) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Heart Valve Diseases (1) · Metabolic Diseases (1)
Clopidogrel (1) · Estradiol (1) · Gabapentin (1) · Gels (1) · Rosuvastatin Calcium (1) · Selective Serotonin Reuptake Inhibitors (1) · Simvastatin (1) · Spironolactone (1) · Ticagrelor (1) · Valsartan (1) · dapagliflozin (1) · fezolinetant (1) · gadopiclenol (1) · oxybutynin (1) · sacubitril and valsartan sodium hydrate drug combination (1)
Azienda Ospedaliero, Universitaria Pisana (1) · Brigham and Women's Hospital (1) · Federal University of São Paulo (1) · Johns Hopkins University (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Tufts Medical Center (1) · University of Washington (1)
United States (3) · Brazil (1) · Italy (1)
Francisco A Fonseca, MD, PhD (1) · Joao Lima, Professor (1) · Martin S Maron, MD (1) · Xue-Qiao Zhao, MD (1)
PMID 29258572, PMID 29604289, PMID 34354179, PMID 34587943, PMID 35421939, PMID 36040917, PMID 37522226, PMID 38585865, PMID 38849829, PMID 41144431, PMID 41629250, PMID 42644318
K23HL168163 (1)